Therapeutic success of tiotropium/olodaterol, measured using the clinical COPD questionnaire (CCQ), in routine clinical practice: A multinational non-interventional study

Arschang Valipour*, Sergey Avdeev, Adam Barczyk, Valentina Bayer, Zvi Fridlender, Mariela Georgieva, Ondřej Kudela, Alexey Medvedchikov, Ramona Miron, Maria Sanzharovskaya, Virginija Šileikienė, Jurij Šorli, Marc Spielmanns, Zsuzsanna Szalai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Background: The Clinical COPD Questionnaire (CCQ) is a simple patient-reported tool to measure clinical control of chronic obstructive pulmonary disease (COPD). Objective: This open-label, single-arm, non-interventional study (NCT03663569) investigated changes in CCQ score during treatment with tiotropium/olodaterol in clinical practice. Methods: Data were included from consenting COPD patients, enrolled in Bulgaria, Czech Republic, Hungary, Israel, Lithuania, Poland, Romania, Russia, Slovenia, Switzerland and Ukraine, who were receiving a new prescription for tiotropium/olodaterol according to the treating physician in a real-world environment. The primary endpoint was the occurrence of therapeutic success, defined as a 0.4-point decrease in CCQ score after treatment with tiotropium/olodaterol for approximately 6 weeks. Results: Overall, 4819 patients were treated; baseline and Week 6 CCQ scores were available for 4700 patients, mostly classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) B (51.6%) or D (42.7%). After 6 weeks’ treatment, 81.4% (95% confidence interval [95% CI] 80.24–82.49) of patients achieved therapeutic success; mean improvement in overall CCQ score was 1.02 points (95% CI 1.00–1.05). Improved CCQ score was seen in 92.2% of patients (95% CI 91.43–92.98), 2.5% had no change and 5.3% showed a worsening. When stratified by prior treatment, the greatest benefit was seen in treatment-naïve patients, with 85.7% achieving therapeutic success, compared with 79.5% of those pretreated with long-acting β2-agonist (LABA)/ inhaled corticosteroid (ICS) and 74.2% of those pretreated with LABA or long-acting muscarinic antagonist (LAMA) monotherapy. Overall, rescue medication decreased by 1.25 puffs/day (95% CI 1.19–1.31) versus baseline. In total, 29 patients (0.6%) reported drug-related adverse events and 7 patients reported serious adverse events (0.15%). Conclusion: In 4700 COPD patients, 6 weeks’ treatment with tiotropium/olodaterol, as initial treatment or follow-up to LAMA or LABA monotherapy or LABA/ICS, improved CCQ and decreased rescue medication use. The adverse event profile was consistent with the known safety profile of tiotropium/olodaterol.

Original languageAmerican English
Pages (from-to)615-628
Number of pages14
JournalInternational Journal of COPD
Volume16
DOIs
StatePublished - 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 Valipour et al.

Keywords

  • CCQ
  • COPD
  • Clinical COPD Questionnaire
  • Noninterventional study
  • Olodaterol
  • Tiotropium

Fingerprint

Dive into the research topics of 'Therapeutic success of tiotropium/olodaterol, measured using the clinical COPD questionnaire (CCQ), in routine clinical practice: A multinational non-interventional study'. Together they form a unique fingerprint.

Cite this